Bisphosphonates in the therapy of fibrous dysplasia. Relevant data and practical aspects;Bisphosphonate in der therapie der fibrösen dysplasie. Relevante daten und praktische aspekte

Orthopade

Volumn 36, Issue 2, 2007, Pages 124-130

  Egner Höbarth, Sigrun ^a   Welkerling, H ^a   Windhager, R ^a  

^a University of Vienna   (Austria)

Author keywords

Bisphosphonate therapy; Bone metabolism; Endocrinopathy; Fibrous dysplasia; Quality of life

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID;

ALBRIGHT SYNDROME; ARTICLE; BONE BIOPSY; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; FIBROUS DYSPLASIA; HUMAN; HYPOCALCEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FIBROUS DYSPLASIA OF BONE; HUMANS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33847408272     PISSN: 00854530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00132-007-1046-y     Document Type: Article

References (25)

1. Bartl R, Frisch B (2001) Das Bisphosphonatmanual. Blackwell Wissenschafts-Verlag, Berlin Wien, S 29-47
2. Chapurlat RD, Meunier PJ, Liens D, Delmas PD (1997) Longterm effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Min Res 12(10): 1746-1752
3. Eugster EA, Rubin SD, Reiter EO et al. (2003) Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 143(1): 60-66
4. Greenspan A (2000) Orthopedic radiology, 3rd edn. Lipincott Williams & Wilkins, Philadelphia, pp 605-611
5. Hannon TS, Noonan K, Steinmetz R et al. (2003) Is McCune-Albright Syndrome overlooked in subjects with fibrous dysplasia of bone? J Pediatr 142(5): 532-538
6. Isaia GC, Lala R, Defilippi C et al.(2002) Bone turnover in children and adolescents with McCune-Albright syndrome treated with Pamidronate for bone fibrous dysplasia. Calcif Tissue Int 71: 121-128
7. Kaushik S, Smoker WRK, Frable WJ (2002) Malignant transformation of fibrous dysplasia into chondroblastic osteosarcoma. Skeletal Radiol 31: 103-106
8. Khadilkar VV, Khadilkar AV, Maskati GB (2003) Oral bisphosphonates in polyostotic fibrous dysplasia. Indian Pediatr 40: 894-896
9. Kos M, Luczak K, Godzinski J, Klempous J (2004) Treatment of monostotic fibrous Dysplasia with pamidronate. J Craniomaxillofac Surg 32(1): 10-15
10. Lane J, Khan SN, O'Connor WJ et al. (2001) Bisphosphonate therapy in fibrous displasia. Clin Orthop Relat Res 382: 6-12
11. Lichtenstein L, Jaffe HL (1942) Fibrous dysplasia of bone. Arch Pathol 33:777-816
12. Liens D, Delmas PD, Meunier PJ (1994) Longterm effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343: 953-954
13. Löffler G, Petrides PE, Heinrich PC (2007) Biochemie und Pathobiochemie, 8. Aufl. Springer, Berlin Heidelberg New York, S 781
14. Mirra JM (1989) Bone tumors. Lea & Febiger, Philadelphia, p 191
15. Parisi MS, Oliveri MB, Acotto CG, Mautalen CA (2001) Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densit 4(2): 167-172
16. Pollandt K, Lohmann CH, Werner M, Delling G (2002) Mazabraud- Syndrom. Pathologe 23: 357-360
17. Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M (2000) A comparative study of fibrous dysplasia and osteofibrous dysplasia Gsalpha mutation at the Arg201 codon: polymerase chain reaction-length polymorphism analysis of paraffin embedded tissues. J Mol Diagn 2(2): 67-72
18. Schwartz DT, Alpert M (1964) The malignant transformation of fibrous dysplasia. Am J Med Sci 247: 1-20
19. Shenker A, Weinstein LS, Sweet DE, Spiegel AM (1994) An activating Gsamutation is present in fibrous dysplasia of bone in the McCuneAlbright syndrome. J Clin Endocrinol Metab 79: 750-755
20. Szendroi M, Rahoty P, Antal I, Kiss J (1998) Fibrous dysplasia associated with intramuscular myxoma (Mazabraud's syndrome): a longterm follow-up of three cases. J Cancer Res Clin Oncol 124: 401-406
21. Weinstein RS (1997) Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Min Res 12(8): 1314-1315
22. Weinstein LS, Shenker A, Gejman PV et al. (1991) Activating mutations of the stimulatory G-protein in the McCuneAlbright syndrome. N Engl J Med 325:1688-1695
23. Yabut SM, Kenan S, Sossons HA, Lewis MM (1988) Malignant transformation of fibrous dysplasia. Clin Orthop 228: 281-289
24. Yamamoto T, Ozono K, Shima M et al. (2002) Alendronate and pharmacological doses of 1aOHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia. J Bone Min Metab 20: 170-173
25. Edwards BJ, Hellstein JW, Jacobsen PL et al. (2006) American Dental Association Council of Scientific Affairs Expert Panal. Dental management of patients receiving oral Bisposphonate therapy. JADA 137: 1144-1150